Clinical impact of dose reductions and interruptions of second- generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
- Author
- SANTOS, Fabio P. S1 ; KANTARJIAN, Hagop1 ; FAVA, Carmen1 ; O'BRIEN, Susan1 ; GARCIA-MANERO, Guillermo1 ; RAVANDI, Farhad1 ; WIERDA, William1 ; THOMAS, Deborah1 ; JIANQUIN SHAN1 ; CORTES, Jorge1
[1] Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, United States - Source
British journal of haematology. 2010, Vol 150, Num 3, pp 303-312, 10 p ; ref : 1 p.3/4
- CODEN
- BJHEAL
- ISSN
- 0007-1048
- Scientific domain
- Medical oncology; Hematology
- Publisher
- Blackwell, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- chronic myeloid leukaemia dasatinib dose intensity dose reduction nilotinib treatment interruption
- Keyword (fr)
- Anticancéreux Dasatinib Dose Homme Hématologie Inhibiteur de la tyrosine kinase Intensité Leucémie myéloïde chronique Nilotinib Traitement Cancer Hémopathie maligne Inhibiteur multikinase Syndrome myéloprolifératif
- Keyword (en)
- Antineoplastic agent Dasatinib Dose Human Hematology Tyrosine kinase inhibitor Intensity Chronic myelogenous leukemia Nilotinib Treatment Cancer Malignant hemopathy Multikinase inhibitor Myeloproliferative syndrome
- Keyword (es)
- Anticanceroso Dasatinib Dosis Hombre Hematología Inhibidor tyrosine kinase Intensidad Leucemia mieloidea crónica Nilotinib Tratamiento Cáncer Hemopatía maligna inhibidor multicinasa Mieloproliferativo síndrome
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases / 002B19B Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
- Discipline
- Blood diseases
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 23050693
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1111/j.1365-2141.2010.08245.x 
https://dx.doi.org/10.1111/j.1365-2141.2010.08245.x
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2141.2010.08245.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:144:\"Clinical impact of dose reductions and interruptions of second- generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"150\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"303\";s:8:\"\u0000*\u0000epage\";s:3:\"312\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"SANTOS\";s:10:\"\u0000*\u0000aufirst\";s:10:\"Fabio P. S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:17:\"KANTARJIAN, Hagop\";i:1;s:12:\"FAVA, Carmen\";i:2;s:14:\"O'BRIEN, Susan\";i:3;s:24:\"GARCIA-MANERO, Guillermo\";i:4;s:15:\"RAVANDI, Farhad\";i:5;s:15:\"WIERDA, William\";i:6;s:15:\"THOMAS, Deborah\";i:7;s:13:\"JIANQUIN SHAN\";i:8;s:13:\"CORTES, Jorge\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:144:\"Clinical impact of dose reductions and interruptions of second- generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2141.2010.08245.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:144:\"Clinical impact of dose reductions and interruptions of second- generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"150\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"303\";s:8:\"\u0000*\u0000epage\";s:3:\"312\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"SANTOS\";s:10:\"\u0000*\u0000aufirst\";s:10:\"Fabio P. S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:17:\"KANTARJIAN, Hagop\";i:1;s:12:\"FAVA, Carmen\";i:2;s:14:\"O'BRIEN, Susan\";i:3;s:24:\"GARCIA-MANERO, Guillermo\";i:4;s:15:\"RAVANDI, Farhad\";i:5;s:15:\"WIERDA, William\";i:6;s:15:\"THOMAS, Deborah\";i:7;s:13:\"JIANQUIN SHAN\";i:8;s:13:\"CORTES, Jorge\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:144:\"Clinical impact of dose reductions and interruptions of second- generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2141.2010.08245.x\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2141.2010.08245.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:144:\"Clinical impact of dose reductions and interruptions of second- generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"150\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"303\";s:8:\"\u0000*\u0000epage\";s:3:\"312\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"SANTOS\";s:10:\"\u0000*\u0000aufirst\";s:10:\"Fabio P. S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:17:\"KANTARJIAN, Hagop\";i:1;s:12:\"FAVA, Carmen\";i:2;s:14:\"O'BRIEN, Susan\";i:3;s:24:\"GARCIA-MANERO, Guillermo\";i:4;s:15:\"RAVANDI, Farhad\";i:5;s:15:\"WIERDA, William\";i:6;s:15:\"THOMAS, Deborah\";i:7;s:13:\"JIANQUIN SHAN\";i:8;s:13:\"CORTES, Jorge\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:144:\"Clinical impact of dose reductions and interruptions of second- generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2141.2010.08245.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:144:\"Clinical impact of dose reductions and interruptions of second- generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:3:\"150\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"303\";s:8:\"\u0000*\u0000epage\";s:3:\"312\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"SANTOS\";s:10:\"\u0000*\u0000aufirst\";s:10:\"Fabio P. S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:17:\"KANTARJIAN, Hagop\";i:1;s:12:\"FAVA, Carmen\";i:2;s:14:\"O'BRIEN, Susan\";i:3;s:24:\"GARCIA-MANERO, Guillermo\";i:4;s:15:\"RAVANDI, Farhad\";i:5;s:15:\"WIERDA, William\";i:6;s:15:\"THOMAS, Deborah\";i:7;s:13:\"JIANQUIN SHAN\";i:8;s:13:\"CORTES, Jorge\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:144:\"Clinical impact of dose reductions and interruptions of second- generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
